Marco Audit is a clinical governance tool that helps hospitals and cancer centers demonstrate that therapeutic decisions in Lung Cancer are evidence-based, consistent with international guidelines and fully auditable. The system generates traceable records of every clinical decision and its bibliographic rationale.
Some answers to questions we often receive
Marco Audit automatically records each relevant clinical query on Lung Cancer: the question asked, evidence consulted, guideline applied and decision made. This record is linked to the case record with full timestamp, creating an auditable decision trail.
Marco Audit generates documentation required by leading oncology accreditation bodies (CoC of American College of Surgeons, ESMO DCNI, national accreditations) to demonstrate evidence-based clinical governance in Lung Cancer, including tumor board records, applied treatment criteria and outcome tracking.
Yes. Marco Audit integrates with the Lung Cancer multidisciplinary tumor board workflow, automatically recording decisions made in committee, evidence presented and participants. It generates structured, verifiable minutes meeting the documentation standards of oncology accreditation bodies.
Yes. Marco Audit generates periodic adherence reports for Lung Cancer at service, unit or institution level: what percentage of decisions align with the NCCN/ESMO standard, where variability is highest, which clinicians or services show atypical patterns, segmentable by period and decision type.
Marco Audit proactively identifies Lung Cancer decisions that deviate from the standard of care without documented justification, generating alerts for clinical review. In the event of legal dispute or audit, the system provides a complete record of evidence consulted and the documented rationale behind each decision.
For payers, Marco Audit provides transparent, structured documentation supporting Lung Cancer treatment authorization requests: the clinical guideline applied, the evidence level of the requested treatment and the consistency of the indication with the patient's molecular profile, reducing review times and coverage disputes.
Lack of traceability in targeted therapy decisions in lung cancer creates medical liability risks and complicates accreditation.